N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers
about
Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeysThe δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptorsNovel GPCR paradigms at the μ-opioid receptorPutative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Discovery of GPCR ligands for probing signal transduction pathways.In vivo opioid receptor heteromerization: where do we stand?GPCR Heterodimerization in the Reproductive System: Functional Regulation and Implication for BiodiversitySynthesis of novel triplets with a 1,3,5-trioxazatriquinane skeleton and their pharmacologies for opioid receptors.Allosteric interactions between δ and κ opioid receptors in peripheral sensory neuronsOpioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behaviorSynergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.Novel 6β-acylaminomorphinans with analgesic activity.Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.G Protein-Coupled Receptor Heteromers.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.History and biological significance of GPCR heteromerization in the neuroendocrine system.G-protein-coupled receptor type A heteromers as an emerging therapeutic target.Breaking barriers to novel analgesic drug development.Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics forBasic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay.Inner Workings: Safer opioids may be on the horizon, but mitigating addiction is a long shot
P2860
Q24597777-4A581536-7F5A-40A4-A7F2-A5FDDBBE23CBQ24630886-35F51ED6-411D-424F-9446-A315A623CCACQ26864286-81A7A3FC-A03B-48FF-AB3F-49A560DEDE74Q34061067-6C3845C7-0B4A-417A-81F3-238000780817Q34125112-6FCACD64-B5EB-413A-8872-9B1C322D229AQ34284204-0AC6FC42-78F5-46CF-8219-18B54B11EE64Q34424009-FDD3ABB3-6523-430C-A7C6-A659D6B32716Q34582707-B1158CA3-4DB1-48BA-8766-D82E6D8D2F57Q34939677-AC391A60-BB67-4711-AFA4-0390BD4FE869Q34962059-86E382EA-80F2-435C-B3ED-966F02EDE4AEQ35627652-F97D4500-9797-4C06-A36A-4488A97ACC34Q35688476-0A86B408-D868-4941-9E69-8F92B45E29F7Q36225640-D50B94E5-4190-4CC0-AAD2-CE41567CDD69Q36296493-4E7B33E9-AB14-4136-A5F6-CFAA76901A03Q36540945-41C9BA20-19C6-4389-B13C-D26908A9EB73Q37340566-367EB22C-1423-45BD-88B9-1752D9AC364BQ37360643-C9AB7BB3-666D-451E-8EDA-AD414D6DCA8DQ37489251-898E7433-4CBD-4C0A-B75F-4ED4A18F943BQ37679197-25321F98-3445-4278-9042-665793E1670CQ37966715-780C8FAE-4EF4-455D-B238-118A87C886E3Q38266283-CA9BF2FD-0936-4307-9858-11E6CDC7A7ADQ39360773-FB84F0B7-1091-4406-BB9A-352E31C95B6CQ41411764-C285D2D0-7A1C-4953-9F4A-8ECF3F60896BQ42633385-0FA9A02C-F964-4BE8-8C91-A8D492A4CC58Q43075742-5DA2E668-E654-493D-AB5E-F8890B46A716Q49754648-5195A2A2-1A01-40D2-B461-3AC21C578F04Q58781851-58BE0FCE-D332-448E-A1C2-5A33BD555472
P2860
N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@ast
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@en
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@nl
type
label
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@ast
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@en
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@nl
prefLabel
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@ast
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@en
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@nl
P2093
P2860
P356
P1476
N-naphthoyl-beta-naltrexamine ...... r of μ/kappa-opioid heteromers
@en
P2093
Ajay S Yekkirala
Alexander E Kalyuzhny
Christopher R McCurdy
Mary M Lunzer
Michael D Powers
Philip S Portoghese
Sandra C Roerig
P2860
P304
P356
10.1073/PNAS.1016277108
P407
P577
2011-03-08T00:00:00Z